Physician profile
Patricia E Laden
NPI 1306823349
$2,736.55
in general payments reported to CMS, 2019-2025
27 companies · $262 in 2025
The $262 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $499 · 2020: $112 · 2021: $505 · 2022: $521 · 2023: $487 · 2024: $352 · 2025: $262.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,100.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $505.57 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $455.04 | 2023-2025 | Myfembree |
| Pfizer INC. | $222.72 | 2022-2024 | |
| Myovant Sciences INC. | $175.16 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $170.83 | 2021-2024 | |
| Evofem Biosciences, INC. | $150.02 | 2020-2024 | |
| Acessa Health INC. | $126.55 | 2019 | |
| Exeltis, USA INC. | $105.60 | 2019-2024 | Slynd |
| Medtronic, INC. | $101.57 | 2022 | |
| Avion Pharmaceuticals | $99.23 | 2019-2023 | Balcoltra |
| Bayer Healthcare Pharmaceuticals INC. | $84.87 | 2019-2022 | |
| Hologic Sales and Service, LLC | $80.10 | 2019-2023 | Thinprep 2000 Processor |
| Astellas Pharma US INC | $70.71 | 2024-2025 | Veozah |
| Biogen, INC. | $53.27 | 2025 | Zurzuvae |
| Millicent US INC | $50.13 | 2020-2025 | Intrarosa, Femring, Femlyv |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $37.22 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $33.58 | 2019 | |
| Exact Sciences Corporation | $31.17 | 2025 | Cologuard Collection Kit |
| Smith+Nephew, INC. | $28.87 | 2021 | |
| Ascend Therapeutics US, LLC | $28.84 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $24.03 | 2025 | |
| Roche Diagnostics Corporation | $22.30 | 2019 | |
| Scynexis, INC. | $17.80 | 2022 | |
| Lupin INC. | $17.04 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $16.65 | 2023 | Exparel |
| Currax Pharmaceuticals LLC | $14.40 | 2024 | Contrave |
| Allergan, INC. | $13.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Laden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.